Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

642 results

• Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing: Complete Statistical AnalysisIndependent statistical analysis of Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02930824).Phase NAResults postedn = 185NCT02930824
• Global Prospective Case Series Using a Single-Use Duodenoscope: Complete Statistical AnalysisIndependent statistical analysis of Global Prospective Case Series Using a Single-Use Duodenoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04103749).Phase NAResults postedn = 551NCT04103749
• GLUMIT-DGIndependent statistical analysis of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01030341).Phase NAResults postedn = 45NCT01030341
• GMTIndependent statistical analysis of Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02486263).Phase NAResults postedn = 76NCT02486263
• GO-COLITISIndependent statistical analysis of Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02092285).Phase 4Results postedn = 205NCT02092285
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 159NCT02252016
• GReaTIndependent statistical analysis of Gene Regulation by Thiazolidinediones: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00567593).Phase 4Results postedn = 12NCT00567593
• Gulf War Digestive Health Study: Complete Statistical AnalysisIndependent statistical analysis of Gulf War Digestive Health Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00680836).Phase NAResults postedn = 54NCT00680836
• GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 31NCT03161379
• HAI115879Independent statistical analysis of Dose Ranging of GSK2336805 in Combination Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01648140).Phase 2Results postedn = 286NCT01648140
• HALO Patient Registry: Ablation of Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of HALO Patient Registry: Ablation of Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00848237).Phase NAResults postedn = 5,521NCT00848237
• Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 49NCT05374876
• HCVIndependent statistical analysis of An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 364NCT00722423
• HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849588).Phase 4Results postedn = 3NCT01849588
• Health Literacy Interventions to Overcome Disparities in CRC Screening: Complete Statistical AnalysisIndependent statistical analysis of Health Literacy Interventions to Overcome Disparities in CRC Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02360605).Phase NAResults postedn = 620NCT02360605
• Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis: Complete Statistical AnalysisIndependent statistical analysis of Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01654549).Phase 2Results postedn = 40NCT01654549
• Hepatic Effects of Gastric Bypass Surgery: Complete Statistical AnalysisIndependent statistical analysis of Hepatic Effects of Gastric Bypass Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00701376).Phase NAResults postedn = 106NCT00701376
• Hepatitis B Booster Study in Adolescence: Complete Statistical AnalysisIndependent statistical analysis of Hepatitis B Booster Study in Adolescence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02169674).Phase 4Results postedn = 359NCT02169674
• Hepatitis C-Video vs. Brochure Education Delivery: Complete Statistical AnalysisIndependent statistical analysis of Hepatitis C-Video vs. Brochure Education Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04204447).Phase NAResults postedn = 176NCT04204447
• hFLCTxIndependent statistical analysis of Human Fetal Liver Cell Transplantation in Chronic Liver Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01013194).Phase 1/2Results postedn = 25NCT01013194
• High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer: Complete Statistical AnalysisIndependent statistical analysis of High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 239NCT01757275
• HORIZON IIIndependent statistical analysis of Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1,254NCT00399035
• Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules: Complete Statistical AnalysisIndependent statistical analysis of Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 47NCT03502070
• Hypnotherapy With Audiofiles for Children and Adolescents With Disorders of Gut-brain Interactions in Sweden -a Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of Hypnotherapy With Audiofiles for Children and Adolescents With Disorders of Gut-brain Interactions in Sweden -a Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 32NCT06493097
• IDEALIndependent statistical analysis of the IDEAL randomized trial of early versus late diet after esophageal variceal ligation in patients with liver cirrhosis, focusing on early rebleeding within 5 days.Phase NAn = 130NCT04890210
• IL-17 Neutrophils in CF Lung Inflammation: Complete Statistical AnalysisIndependent statistical analysis of IL-17 Neutrophils in CF Lung Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02025829).Phase NAResults postedn = 14NCT02025829
• IMIndependent statistical analysis of Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01499576).Phase NAResults postedn = 126NCT01499576
• IMMULAB – Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 30NCT03753659
• Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,474NCT00197015
• Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis: Complete Statistical AnalysisIndependent statistical analysis of Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01773967).Phase 2/3Results postedn = 971NCT01773967
• Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery: Complete Statistical AnalysisIndependent statistical analysis of Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 70NCT02533167
• IMPROVE-LapIndependent statistical analysis of A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02058290).Phase 4Results postedn = 122NCT02058290
• Improving Bowel Preparation for Colonoscopy With a Simple Educational Card: Complete Statistical AnalysisIndependent statistical analysis of Improving Bowel Preparation for Colonoscopy With a Simple Educational Card: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00643682).Phase NAResults postedn = 2,000NCT00643682
• Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management: Complete Statistical AnalysisIndependent statistical analysis of Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 66NCT06068426
• Increasing Activity in Liver Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Increasing Activity in Liver Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02058498).Phase NAResults postedn = 12NCT02058498
• Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients: Complete Statistical AnalysisIndependent statistical analysis of Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 36NCT00871845
• Individualized Stereotactic Body Radiotherapy of Liver Metastases: Complete Statistical AnalysisIndependent statistical analysis of Individualized Stereotactic Body Radiotherapy of Liver Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01239381).Phase NAResults postedn = 92NCT01239381
• Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 625NCT03440372
• Influence of IPV on GOR in Infants From 0 to 12 Months.: Complete Statistical AnalysisIndependent statistical analysis of Influence of IPV on GOR in Infants From 0 to 12 Months.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 67NCT02124863
• Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection: Complete Statistical AnalysisIndependent statistical analysis of Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 68NCT02716779
• Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy: Complete Statistical AnalysisIndependent statistical analysis of Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 40NCT03380572
• INSIGHTIndependent statistical analysis of A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 24NCT04585789
• InspirAdaIndependent statistical analysis of A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting: primary…Phase 3Results postedn = 463NCT01550965
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.: Complete Statistical AnalysisIndependent statistical analysis of Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 320NCT02970942
• Ipilimumab and Local Radiation for Selected Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Ipilimumab and Local Radiation for Selected Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01769222).Phase 1Results postedn = 3NCT01769222
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery: primary endpoint results,…Phase 2Results postedn = 36NCT02292758
• Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 55NCT00062374
• Isoflurane Preconditioning for Liver Resections: Complete Statistical AnalysisIndependent statistical analysis of Isoflurane Preconditioning for Liver Resections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01031550).Phase NAResults postedn = 8NCT01031550
• JACOBIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer: primary endpoint…Phase 3Results postedn = 780NCT01774786
• JUNIPERIndependent statistical analysis of Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 790NCT02403323

← All therapeutic areas